Association of Serum Renalase Levels and Renalase rs10887800 Polymorphism with Unstable Angina Pectoris Patients Having Metabolic Syndrome.

PURPOSE: An increased risk of cardiovascular mortality and morbidity has been linked with metabolic syndrome (MetS), described as the secondary risk reduction target. These patients are predisposed to high complication levels such as unstable angina-pectoris (USAP) by MetS. As with the role of renalase in the regulation of blood pressure (BP), the study was carried out to determine the levels of renalase circulation in patients with USAP and MetS (USAP+MetS), as well as the association of renalase gene (RNLS) rs10887800 polymorphism and USAP and MetS susceptibility. PATIENTS AND METHODS: A total of 134 patients with USAP+MetS and 134 control subjects were recruited in this case-control study.
RESULTS: Renalase was found to have a significantly higher level in USAP+MetS patients (23.28 ± 4.09 µg/dL) than in healthy ones (20.81 ± 2.73 µg/dL) (P < 0.001). Also, it was shown that renalase sensitivity and specificity values for the early diagnosis of USAP and MetS seemed to be 53.7% and 76.9, respectively. Moreover, the value for renalase area under curve (AUC) was 0.654 (95% CI: 0.58-0.72). The frequency of rs10887800 AG and GG genotypes of RNLS gene was significantly higher in USAP+MetS patients than in control subjects, suggesting that this genotype might be a risk factor against USAP+MetS (OR = 2.114 [95% CI 1.113-4.016]; P = 0.022) and (OR = 2.057 [95% CI 1.011-4.186]; P = 0.047), respectively.
CONCLUSION: The present results showed that renalase serum levels increased in USAP and MetS patients. Moreover, the RNLS rs10887800 was reported to be associated with a higher risk of USAP+MetS.

Introduction

Metabolic syndrome (MetS) is a variety of conditions which occur simultaneously and include abdominal obesity, hyperglycemia, dyslipidemia, and hypertension. Such conditions lead to an increased risk of heart disease, stroke, and diabetic status.1 MetS is clinically important in terms of detecting a subgroup of patients who have in common a physiopathological state which makes them suffer from chronic diseases.2 Unfortunately, the prevalence of MetS has increased in recent years. According to an enormous number of studies, the prevalence of MetS in a variety of countries ranged from 12.8% to 41.7%, while in Iran it was shown to vacillate between 22% and 31%.3,4 Moreover, unlike the developed countries, Iran has seen a 20% to 45% increase in the level of cardiovascular mortality over the past 20 years,5,6 which is partially due to the prevalence of MetS. In addition, MetS causes a threefold rise in the risk of diabetes; thus, the crucial role the diagnosis of this syndrome plays in the prevention of diabetes and cardiovascular diseases (CVDs).7

Ischemic heart diseases are comprised of a vast variety of conditions ranging from asymptomatic ischemia, exertion-induced angina, and unstable angina pectoris (USAP), to acute myocardial infarction (MI).8 Being on the top of this list, USAP causes disability and some other risks which are greater than those created by chronic stable angina pectoris (SAP), but less than those of acute MI. Not only is USAP very prevalent, but it is also regarded as a quite serious form of acute coronary syndrome (ACS). Furthermore, it accounts for huge numbers of hospitalization in the United States, that is, more than an annual number of 750,000 hospitalized cases, from which 70,000 patients develop MI, leading to their sudden death.1,9,10 USAP is mainly diagnosed in a clinical way and on the basis of symptom recognition.11 Inflammatory mediators are inextricably linked to the sequence of events that contribute to formation, progression, and fracture of atherosclerotic plaque. This understanding has spurred examination of many inflammation markers as prospective instruments for the prediction of the risk of CVD, of which renalase is the most persistently researched. Therefore, the incidence of USAP and MetS is determined by an intricate association between genetic, metabolic, and environmental factors.12,13

CVDs have been reported to witness a rise in the level of catecholamines. Also, it is shown that catecholamines, namely norepinephrine, epinephrine, and dopamine, are involved in regulating blood pressure (BP).12 Intracellular enzymes, including catechol-O‐methyltransferase, monoamine oxidase‐A (MAO‐A), and MAO‐B, are involved in the degradation of catecholamines. Renalase, which was developed by Xu et al,13 is a truly innovative monoamine oxidase enzyme as well as a soluble dinucleotide-dependent amine oxidase flavin adenine. Research has revealed that the increase in the level of plasma catecholamines greatly increases renalase performance which supports renalase’s contribution to circulation of catecholamine degradation, as well as controlling BP and cardiac activity.14

A considerable array of evidence has shown that USAP and MetS are partially determined in a genetic manner.15–18 An understanding of the precise genetic factors inherent in development of USAP and MetS may possibly explain why USAP and MetS features often co-occur within the same particular person. It is noteworthy that many genetic variants have been investigated to determine the genes influencing the development of USAP and MetS with contradictory results; nevertheless, no study has been conducted on the possible implications of the renalase gene (RNLS) polymorphisms and USAP and/or MetS. RNLS on chromosome 10q23.33 is identified as a human renalase enzyme that encodes genes which has 309, 469 base pairs (bp), and 10 exons.14

A theory which has attempted to describe the elevated BP in MetS, likely to be included in USAP pathogenesis, has been proposed in this regard. Based on the prior research, the increased activity of sympathetic vasoconstrictors is a crucial mechanism that enhances vascular resistance. With respect to the involvement of renalase in BP regulation, in the current study, we assessed firstly the association between single-nucleotide polymorphism (SNP) of RNLS rs10887800 at intron 6 close to the exon/intron border and susceptibility of USAP and MetS (USAP+MetS) in southern Iran. Additionally, we sought to determine the renalase circulation levels in USAP and MetS patients.

Materials and Methods

Subjects

This case-control research was conducted on 268 participants who referred to Emergency Units of Namazi and Al-Zahra Heart Hospitals affiliated to Shiraz University of Medical Sciences, Shiraz, Iran. The research involved 134 subjects with USAP+MetS (55 men and 79 women, mean age = 56.88 ± 9.25 years), and 134 healthy subjects (64 men and 70 women, mean age = 53.50 ± 8.50 years). Patients who suffered from chest pain volunteered to take part in the research, so they were physically checked by cardiologist and/or an emergency physician. Patients that fulfilled the following therapeutic requirements were regarded as USAP cases: admission to hospital with angina pectoris or a comparable ischemic pain with at least one of three attributes (1) having taken place at rest (or with relatively low exertion), commonly lasting >10 minutes; (2) being severe and new (ie, within 4–6 weeks); and/or (3) having happened with a crescendo trend (ie, clearly more severe, prolonged, or frequent than before). In addition, MetS was taken into consideration in compliance with the scientific criteria set by the American Heart Association.19 Participants with three or more of the following three factors are identified as MetS: 1) high waist circumference (WC) (85 and 80 cm in men and women, respectively); 2) high triglycerides (TG) (≥150 mg/dL (1.7 mmol/l)) or drug therapy; 3) high-density lipoprotein cholesterol (HDL-c) (<40 mg/dL (1.0 mmol/L) in males (<50 mg/dL (1.3 mmol/L) in females) or drug therapy; 4) high BP (systolic blood pressure (SBP) 130 mmHg and/or diastolic blood pressure (DBP) 85 mmHg) or taking antihypertensive medication; 5) fasting glucose (≥100 mg/dL (5.56 mmol/L)) or drug therapy.19

Subjects of insufficient medical and demographic information, discontented participants and those under hormone replacement therapy or afflicted with congenital heart disease, chronic kidney disease (CKD), respiratory diseases, strokes, cancers, autoimmune diseases, thyroid disease and chronic hepatic condition were all excluded from the study. After exclusion, 134 patients with USAP+MetS and 134 healthy subjects were included in the data analyses. This research was approved by the local Ethics Committee of Shiraz University of Medical Sciences, Shiraz, Iran (IR.sums.med.rec.1398.661), and was undertaken based on the principles of the Helsinki Declaration. We received a signed informed consent.

Anthropometric and Biochemical Measurements

BP of all subjects was measured from the right arm using a mercury sphygmomanometer after at least a five-minute rest and was repeated at a minimum five-minute interval, and then the mean pressure was used. The WC was evaluated at the level of the iliac crest and at the end of a normal expiration of the subject with a measuring tape in a horizontal plane around the abdomen. The weight of participants was gauged using the lowest possible clothing while being barefoot with a 100g accuracy digital scale. The height of subjects was measured by a measuring tape with an accuracy of 1cm while standing beside the wall, and their shoulders in normal position.

At the time of admission, 10 milliliter fasting blood samples were extracted from each patient, of which 5cc was preserved in tubes that included ethylenediaminetetraacetic acid (EDTA) anticoagulant for DNA extraction at −20°C and the remaining 5cc was centrifuged at room temperature for a few minutes (at 2500 rpm for 7 min). The serum samples were then kept at −70°C until assessment of the renalase. Regular laboratory tests were used to measure the fasting blood glucose (FBG), TG, and HDL-c.

Measurement of Renalase

The concentration of serum renalase was determined by means of an enzyme-linked immunosorbent assay (ELISA) kit (USCN Life Science Inc., Wuhan, China) comprised of commercially available FAD-dependent amine oxidase, as directed by the manufacturer. Note that renalase serum amounts were measured in μg/mL.

Genotype Determination

Genomic DNA from the whole blood samples (obtained from EDTA-anticoagulated blood) was collected using the “salting-out” process. The polymerase chain reaction-restriction fragment length polymorphism (PCR‐RFLP) method outlined below was also used to establish genotypes of RNLS rs10887800 polymorphism. Bagci et al20 reported the primers’ sequences that were used to amplify DNA fragments. The PCR parameters were as follows: initial denaturation at 95°C for 5 minutes accompanied by 30 amplification cycles comprising 95°C denaturation, 60°C annealing, 72°C extension (30 seconds each), and 5 minutes ultimate extension at 72°C. PCR products (10 μL) were digested at 37°C for 1 hour with 5 U of PstI restriction endonuclease (Jena Bioscience, Jena, Germany) and particles were segregated in the TBE 0.5 X buffer by electrophoresis with 1.6% (w/v) ethidium bromide-stained agarose gel. They were later envisioned by ultraviolet light. The RNLS 10887800A allele had no PstI cleavage site and produced only a 554‐bp fragment. The RNLS 10887800G, however, had two PstI cleavage site, creating 139‐bp and 415‐ digested fragments (Figure 1).

Figure 1

Gel electrophoresis of RNLS rs10887800 gene polymorphism. AA genotype (139 bp); AG genotype (139 bp, 415 bp, and 554 bp); GG genotype (139 bp and 415 bp).

Statistical Analysis

All the statistical procedures were executed by means of the statistical package for the social sciences (SPSS) version 23.0 for Windows (SPSS Inc., Chicago, IL). Note that a p-value lower than 0.05 was set as significant. The Kolmogorov–Smirnov test was employed to examine the assumption of normality. All continuous variables were mentioned as mean ± standard deviation (M±SD) and categorical variables in the form of numbers (percentages). Comparisons of anthropometric indices, laboratory biomarkers, and renalase serum levels between the two groups of participants were made through Chi-square test for categorical variables and the Student’s t-test or Mann–Whitney U-test for continuous ones. The discrepancies between subgroups were studied utilizing Kruskal–Wallis with post-hoc Mann–Whitney U-tests as well as Chi-square/Fisher’s exact tests (applying the Bonferroni correction). Deviation from the Hardy–Weinberg equilibrium (HWE) was tested by the Chi-square test. Moreover, correlations between MetS components and renalase were assessed as necessary through the Spearman test and, also, to achieve a renalase cutoff value for USAP+MetS prediction, receiver operating characteristic (ROC) curve was used. Finally, the logistic regression model was used to investigate the association between the study groups with allele and genotype frequencies. Crude and adjusted odds ratios (OR) were estimated through simple and multiple models adjusted for age, sex, BMI, SBP, DBP, FBS, TG, HDL-c, and WC.

Results

Table 1 outlines the medical characteristics for patients and healthy subjects. There were no significant age discrepancies (56.88 ± 9.25 years for the case and 53.50 ± 8.50 years for controls) and sex differences between the case and control groups (P= 0.09 and P= 0.32, respectively), while BMI was significantly higher in USAP+MetS patients than in control patients (P < 0.001). All the components of MetS varied significantly between the two categories (P < 0.001).

Table 1

Comparison of Anthropometric Indices, Laboratory Biomarkers, and Renalase Serum Levels Between USAP+MetS and Control Subjects

	USAP+MetS (n=134)	Control (n=134)	P-value
Age, years	56.88 ± 9.25	53.50 ± 8.50	0.09
Sex (m/f)	55/79	64/70	0.32
BMI, kg/m2	31.53 ± 5.25	26.86 ± 4.04	<0.001*
WC, cm	100.55 ± 9.54	87.15 ± 8.78	<0.001*
FBG, mg/dL	113.96 ± 47.73	83.11 ± 11.65	<0.001*
TG, mg/dL	271.31 ± 179.09	136.14 ± 62.02	<0.001*
HDL, mg/dL	41.01 ± 8.88	50.00 ± 11.98	<0.001*
SBP, mmHg	132.81 ± 16.48	117.16 ± 19.19	<0.001*
DBP, mmHg	82.22 ± 9.26	76.58 ± 8.23	<0.001*
Renalase, µg/dL	23.28 ± 4.09	20.81 ± 2.73	<0.001*

Notes: Quantitative data were shown as the mean and standard deviation (mean ± SD) and qualitative data were presented as counts; *Significant difference (P value < 0.05).

Abbreviations: USAP+MetS, unstable angina pectoris and metabolic syndrome; BMI, body mass index; WC, waist circumference; FBG, fasting blood glucose; TG, triglycerides; HDL-c, high-density lipoprotein cholesterol; SBP, systolic blood pressure; DBP, diastolic blood pressure; Cr, creatinine.

Serum renalase levels between the two groups can be seen in Figure 2. Renalase has been shown to have significantly higher levels in patients with USAP+MetS (23.28 ± 4.09 μg/dL) compared to the healthy ones (20.81 ± 2.73 µg/dL) (P < 0.001). As can be seen in Figure 3, there were no significant differences in renalase levels between men and women in each group (P = 0.13 for case group and P = 0.07 for control one), while men exhibited higher levels of renalase compared with women.

Figure 2

Comparison of renalase serum levels between unstable angina pectoris and metabolic syndrome (USAP+MetS) patients and control individuals.

Figure 3

Comparison of renalase serum levels between unstable angina pectoris and metabolic syndrome (USAP+MetS) and control groups divided by gender.

Table 2 demonstrates the comparison of demographic factors, clinical laboratory parameters and serum renalase levels between MetS components. Other factors, apart from sex (P = 0.50) including BMI, WC, FBG, TG, HDL, SBP, DBP, and renalase differed significantly between MetS components (P = 0.002 for age and P < 0.001 for all comparisons). Besides, no significant correlation was found between the components of MetS and renalase (data are not shown).

Table 2

Comparison of Anthropometric Indices, Laboratory Biomarkers, and Renalase Serum Levels Among MetS Components

	0 MetS Components (n=32)	1 MetS Components (n=53)	2 MetS Components (n=49)	3 MetS Components (n=74)	≥4 MetS Components (n=60)	P-value
Age, years	51.61 ± 5.18	54.34 ± 8.69	‌53.80 ± 9.61	55.84 ± 9.97	58.17 ± 8.17	0.002
Sex (m/f)	17/15	24/29	23/26	34/40	21/39	0.50
BMI, kg/m2	24.37 ± 3.31	26.98 ± 4.07	28.30 ± 3.75	30.13 ± 4.07	33.25 ± 6.01	<0.001*
WC, cm	81.35 ± 9.63	87.03 ± 7.74	90.95 ± 7.24	97.15 ± 8.67	104.75 ± 8.94	<0.001*
FBG, mg/dL	80.26 ± 7.71	81.87 ± 8.48	86.27 ±15.52	99.73 ± 41.16	131.52 ± 49.72	<0.001*
TG, mg/dL	94.55 ± 22.74	126.51 ± 39.69	172.88 ± 77.14	268.70 ± 174.07	274.53 ± 186.52	<0.001*
HDL-c, mg/dL	57.55 ± 10.01	51.08 ± 10.36	44.06 ± 11.89	42.18 ± 9.76	39.57 ± 7.49	<0.001*
SBP, mmHg	106.29 ± 11.83	115.57 ± 13.72	125.77 ± 23.81	130.54 ± 15.47	135.61 ± 17.37	<0.001*
DBP, mmHg	72.26 ± 5.60	75.94 ± 7.42	80.00 ± 9.08	81.93 ± 9.30	82.58 ± 9.27	<0.001*
Renalase, µg/dL	20.43 ± 2.58	20.86 ± 3.00	21.01 ± 2.53	22.99 ± 4.27	23.63 ± 3.86	<0.001*

Notes: Quantitative data were depicted as the mean ± standard deviation (mean ± SD) and qualitative data were presented as counts; *Significant difference (P value < 0.05).

Abbreviations: MetS, metabolic syndrome; BMI, body mass index; WC, waist circumference; FBG, fasting blood glucose; TG, triglycerides; HDL-c, high-density lipoprotein cholesterol; SBP, systolic blood pressure; DBP, diastolic blood pressure.

Figure 4 illustrates the comparison of renalase serum levels among MetS components. It was also found that zero (20.43 ± 2.58 μg/dL) and one (20.86 ± 3.00 μg/dL) MetS component groups significantly differ from four and five (23.63 ± 3.86 μg/dL) MetS components (P = 0.01 and P = 0.004) in terms of renalase serum levels.

Figure 4

Comparison of renalase serum levels between MetS components in patients with unstable angina pectoris and metabolic syndrome (USAP+MetS). *Significant differences with 4 and 5 components group. In comparison with four- and five-component of metabolic syndrome group, the patients with zero and one metabolic syndrome components showed significantly lower renalase serum levels (P = 0.011 and P = 0.004, respectively).

We also described the ROC curve by comparing the specificity and sensitivity of renalase for USAP+MetS diagnoses (Figure 5). Renalase sensitivity and specificity for the early diagnosis of USAP and MetS seemed to be 53.7% and 76.9%, respectively. Renalase area under curve (AUC) was 0.654 (95% CI: 0.58–0.72). The findings indicated that the ideal serum renalase cut-off value for USAP+MetS diagnosis was 22.45 μg/dL.

Figure 5

Receiver operating characteristic (ROC) curve in diagnosing unstable angina pectoris and metabolic syndrome (USAP+MetS). Values of 22.45 or greater predicted critical USAP+MetS with a sensitivity of 53.7% and a specificity of 76.9% (area under curve: 0.654).

Table 3 depicts the allelic and genotypic levels of polymorphism in participants with and without USAP+MetS. The frequency of the RNLS genotype rs10887800 AG was significantly higher in USAP+MetS patients than in control subjects and this genotype might also constitute a risk factor against USAP+MetS (OR = 2.11 [95% CI 1.11–4.01]; P = 0.02). Similarly, the prevalence of the RNLS rs10887800 GG genotype in USAP+MetS patients demonstrated a significantly higher number relative to control subjects, implying that this genotype possibly functions as a risk factor against USAP+MetS (OR = 2.05 [95% CI 1.01–4.18]; P = 0.04). In the adjusted model, we also found that the prevalence of RNLS rs10887800 G allele was greater in USAP+MetS patients compared to the control group (57% vs 49%, respectively) (OR = 1.57 [95% CI 1.04–2.36]; P = 0.03). In the adjusted dominant genetic model, the AG + GG genotypes were correlated with 4.14 times higher odds of USAP+MetS (OR = 4.14, [95% CI = 1.29–13.23], P = 0.01). Although the crude recessive model showed no significant association with USAP+MetS risk (P= 0.49), adjusted model demonstrated an increased association with USAP+MetS risk (OR = 1.57 [95% CI 1.04–2.36]; P = 0.01). In addition, there were no significant discrepancies in HWE deviation of genotypic frequencies either in the USAP+MetS or in the control groups (P > 0.05).

Table 3

Genotype and Allele Frequencies of RNLS Rs10887800 Polymorphism in Subjects with USAP+MetS and Control Groups

	USAP+MetS (n = 134)	Control(n = 134)	P-value	OR (95% CI)
RNLS rs10887800
AA, n (%)	20 (14.9)	36 (26.9)		1
AG, n (%)	74 (55.2)	63 (47.0)	0.02*	2.114 (1.113–4.016)
GG, n (%)	40 (29.9)	35 (26.1)	0.04*	2.057 (1.011–4.186)
Crude recessive model(GG vs AG+AA)			0.49	1.20 (0.07–2.05)
Adjusted recessive model¥(GG vs AG+AA)			0.01*	1.57 (1.04–2.36)
Crude dominant model(AG+GG vs AA)			0.01*	2.09 (1.13–3.85)
Adjusted dominant model¥(AG+GG vs AA)			0.01*	4.14 (1.29–13.23)
Crude allelic model
A, n (%)	114 (42.5)	135 (50.4)		1
G, n (%)	154 (57.5)	133 (49.6)	0.07	1.40 (0.97–1.91)
Adjusted allelic model¥			0.03*	1.57 (1.04–2.36)
X2	2.25	0.47
P-value of HWE	0.13	0.49

Notes: Qualitative data were presented as counts (percentage); *Significant difference (P value < 0.05); ¥Adjusted for age, sex, BMI, SBP, DBP, FBS, TG, HDL, and WC.

Abbreviations: USAP+MetS, unstable angina pectoris and metabolic syndrome; HWE, Hardy–Weinberg equilibrium.

A summary of mean values for the clinical and anthropometric variables analyzed in USAP+MetS and control subjects according to RNLS rs10887800 genotypes (Tables 4 and 5, respectively). There were no significant differences in the variables tested (MetS components) in terms of the three RNLS rs10887800 genotypes in both studied groups (P > 0.05).

Table 4

Comparison of Mean Values of the Examined Parameters According to RNLS Rs10887800 Genotypes in USAP+MetS Subjects

	AA (n=20)	AG (n=74)	GG (n=40)	P-value
Age, years	55.7 ± 8.96	56.95 ± 8.53	57.33 ± 10.73	0.82
Sex (m/f)	10/10	29/45	16/24	0.71
BMI, kg/m2	33.52 ± 7.98	31.35 ± 4.77	30.86 ± 4.22	0.52
WC, cm	102.59 ± 6.95	100.61 ± 9.91	99.42 ± 9.99	0.38
FBG, mg/dL	117.00 ± 54.83	117.95 ± 52.85	105.08 ± 31.09	0.93
TG, mg/dL	244.15 ± 118.68	301.28 ± 217.77	229.45 ± 99.35	0.24
HDL, mg/dL	42.65 ± 9.20	39.47 ± 8.52	43.03 ± 9.04	0.06
SBP, mmHg	130.75 ± 14.89	132.74 ± 18.10	133.98 ± 14.19	0.67
DBP, mmHg	81.75 ± 8.55	82.33 ± 9.45	82.25 ± 9.45	0.89
Renalase, µg/dL	24.07 ± 3.90	23.40 ± 4.11	22.66 ± 4.13	0.27

Notes: Quantitative data were illustrated as the mean ± standard deviation (mean ± SD) and qualitative data were presented as counts.

Abbreviations: USAP+MetS, unstable angina pectoris and metabolic syndrome; BMI, body mass index; WC, waist circumference; FBG, fasting blood glucose; TG, triglycerides; HDL-c, high-density lipoprotein cholesterol; SBP, systolic blood pressure; DBP, diastolic blood pressure.

Table 5

Comparison of Mean Values of the Examined Parameters According to RNLS Rs10887800 Genotypes in Control Subjects

	AA (n=20)	AG (n=74)	GG (n=40)	P-value
Age, years	53.80 ± 9.00	53.56 ± 7.64	53.11 ± 9.62	0.95
Sex (m/f)	21/15	28/35	15/20	0.32
BMI, kg/m2	27.85 ± 5.55	26.92 ± 3.86	26.38 ± 4.38	0.37
WC, cm	89.69 ± 9.07	86.67 ± 7.80	85.48 ± 9.78	0.62
FBG, mg/dL	85.49 ± 9.61	81.25 ± 11.90	84.09 ± 12.76	0.19
TG, mg/dL	156.34 ± 84.00	131.25 ± 52.49	124.74 ± 47.49	0.08
HDL, mg/dL	46.29 ± 10.46	50.67 ± 12.76	52.51 ± 11.35	0.07
SBP, mmHg	116.21 ± 18.23	116.31 ± 16.74	119.64 ± 24.04	0.64
DBP, mmHg	77.21 ± 8.96	75.99 ± 7.00	77.00 ± 9.58	0.80
Renalase, µg/dL	21.11 ± 3.00	20.71 ± 2.63	20.79 ± 2.70	0.78

Notes: Quantitative data were illustrated as the mean ± standard deviation (mean ± SD) and qualitative data were presented as counts.

Abbreviations: BMI, body mass index; WC, waist circumference; FBG, fasting blood glucose; TG, triglycerides; HDL-c, high-density lipoprotein cholesterol; SBP, systolic blood pressure; DBP, diastolic blood pressure.

Discussion

The manifestation, development and severity of USAP and MetS rely on hereditary predisposition in combination with metabolic and environmental factors.13 The detection of MetS genetic/metabolic risk factors is therefore important for USAP and other threatening diseases to be predicted at risk. As one of the metabolic factors that cause different metabolic diseases, renalase is regarded as an innovative indicator that interferes with different metabolic mechanisms. The current research thus aimed to exam the probable association of the circulating level of renalase and its RNLS rs10887800 polymorphism with USAP and MetS. The key results of the current study revealed that higher renalase levels correlate with USAP and MetS. In addition, both AG and GG genotypes of RNLS rs10887800 polymorphism displayed a risk factor impact with an elevated risk of USAP and MetS in 2.114 and 2.057 times. Even though there were significant associations between MetS components and renalase levels, no significant relationship was reported between MetS components and RNLS rs10887800 genotypes.

MetS has found to be related to an increased likelihood of cardiovascular mortality and morbidity and has since been established as a secondary risk reduction target.21 In acute coronary syndrome (ACS), MetS incidence increases to approximately 50%, and MetS makes it possible for such patients to suffer from higher complication levels (eg, heart failure, stroke, and mortality).22,23 Several studies have examined the impact of MetS on MI, but none involved individuals with pure non-ST segment myocardial infarction (NSTEMI) and an unstable angina pectoris (USAP). As the main aim of the current study, the investigation of renalase circulating level was performed as a probable predictor biomarker in diagnosing the USAP patients by MetS baseline. Renalase is a flavoprotein amine oxidase comprising 342 amino acids, indicated to be active in the metabolism of catecholamines. Evidence seems to suggest that this enzyme is secreted into the body by kidneys. This enzyme is, nevertheless, also present in the heart, intestine, liver, skeletal muscle, and endothelium. The enzyme plays a pivotal role in circulating the degradation of catecholamines, consequently leading to a significant drop in BP as well as other main medical issues such as MetS.24–26 According to the evidence, the plasma lacks sufficient renalase activity in humans under basal circumstances; however, its activity might be enhanced nearly 10-fold in 30 seconds through infusion of exogenous epinephrine for at least 60 minutes.14 In addition, evidence suggests that plasma renalase is stimulated in reaction to greater systolic BP, thereby implying that this enzyme plays a significant role in the minute-to-minute regulation of BP.27 Studies have shown that hypertension is associated with renalase deficiency. Tachycardia and hypertension were seen in a renalase knockout mouse model, confirming the role of renalase in regulating BP.14

Both experimental and clinical studies have confirmed the relationship between serum renalase and pressure of the blood and other metabolic factors; although the findings are still vague. Also, for patients with USAP and MetS, current results have shown higher levels of renalase than those of the control ones. Moreover, in experimental models, renalase was reported to play a role in hypertension pathogenesis and it was Zhao et al28 who first demonstrated the relationship between renalase and hypertension. In 2586 adult Chinese population, however, the data in whites have not been verified.29 Renalase deficiency in hypertension and CKD were later displayed by Ficek et al.28 Independently, Wybraniec et al29 reported that the occurrence of hypertension in a patient following surgical reparation of aortic coarctation as well as in a control group was correlated with inadequate renalase. The results of the aforementioned studies show that the regulation of the intrarenal dopaminergic system can be accounted for by the effect of renalase. The findings of this study showed the higher levels of renalase in MetS and USAP patients. Therefore, it is possible, according to the findings of the aforementioned studies, that the renalase rises in emergency conditions such as USAP are due to body metabolic changes.

Findings obtained from the current study showed that circulating renalase levels in USAP+MetS patients were significantly higher than in healthy subjects. In this respect, men have shown higher renalase levels in both USAP+MetS and control groups compared to women, even though this difference was not significant. To the best of authors’ knowledge, this is the first study to investigate the association between renalase serum levels and USAP+MetS and its components. In addition, our analysis also established the diagnostic sensitivity and specificity of renalase in USAP and MetS cases for the first time. With regard to ROC analysis, renalase could not be regarded as a good diagnostic biomarker for predicting coronary intervention outcomes in USAP patients with syndrome X. In our research, given the accepted function of catecholamines in atherosclerosis and other CVDs, it is speculated that higher renalase levels could contribute to mitigating emergency cardiovascular conditions including USAP, especially in patients with MetS. It should be noted that, like ours, several studies have shown a high serum renalase level, although diagnostic values of such biomarkers for USAP have still not been adequately made clear, highlighting the need for further research projects to confirm the current results.

The RNLS (length 309 469 bp) is located at q23.33 on chromosome 10. This gene contains 10 exons with at least four alternatively spliced isoforms. Expressed more than other renalases and having a length of 342 amino acids, renalase 1 isoform is mainly found in plasma, kidney, skeletal muscle, heart, and liver.14,28 Different SNPs including rs10887800, rs2576178, rs2296545 and rs2114406 are present in the RNLS gene, and their association with hypertensive, vascular, diabetes, and stroke has been the focus of many studies.29–31 Even though the RNLS rs10887800 polymorphism was investigated under various conditions and in different population groups, the specific mechanism through which polymorphism altered the risk of USAP and MetS remains unspecified. The renalase rs10887800 examined by SNP is placed close to the exon/intron boundary in a putative functional region. Thus, it is possible that it influenced gene regulation and expression, leading to changes in the amount of renalase levels.31,32

The number of RNLS rs10887800 GG and RNLS rs10887800 AG genotypes in this analysis was found to be significantly higher for USAP+MetS patients. Also, it has been shown that the adjusted recessive and dominant genetic models for RNLS rs10887800 polymorphism proved to play a risk factor role against the USAP and MetS. Furthermore, the current findings did not demonstrate the association between serum renalase levels and genotypes of renalase rs10887800. Stec et al31 conducted a study on the relationship between RNLS rs10887800 gene polymorphism and renalase circulation levels in patients who were being under hemodialysis. Their results showed significantly lower renalase levels in hemodialysis of the genotype rs10887800AA compared to those of GG and AG. Nevertheless, this polymorphism did not indicate any correlation with regard to the control group’s renalase concentration which was in line with findings of the current study. In the present study, RNLS rs10887800 polymorphism was shown to be associated with USAP+MetS development in such that higher risk for USAP+MetS was associated with the RNLS rs10887800 AG and GG genotypes.

The most crucial MetS parameters related with renalase functioning were the mean of SBP and DBP24,26,33 and FBG33 which are fully studied previously. In this respect, the examination of RNLS rs10887800 polymorphism in combination with MetS components showed that the genotype distributions of rs10887800 were not correlated with MetS components. While numerous studies have found a correlation between different polymorphisms with RNLS and other diseases, no published research has been reported on the likely association between MetS, USAP, and RNLS gene polymorphism. Studies conducted by Bagci et al20 on Turkish population along with that of Teimoori et al24 on an Iranian population revealed that in women with preeclampsia, the genotype rs10887800 GG was significantly higher in SBP and DBP than in the GA or AA, both of which were not in accordance with this study. In another research by Buraczynska et al,30 the relationship of renalase rs2296545, rs2576178 and rs10887800 SNPs were investigated with the gene polymorphism for patients with type 2 diabetes, hypertension and stroke, showing that polymorphism with RNLS rs10887800 G allele could be helpful in identifying diabetes patients at an increased risk of stroke. While the possible link between RNLS polymorphism and clinical laboratory parameters was not explored in their study, our findings did not show the association between levels of FBG serum and RNLS rs10887800 genotype distributions. Although the mechanism behind the impact of RNLS rs10887800 polymorphism on hypertension and consequently, on the development of USAP and MetS could not be readily apparent, they may influence renalase enzyme expression or activity. Polymorphism rs10887800 is indicated to be located near an exon/intron boundary in a putative functional region and could therefore impact on gene expression and cause changes in the renalase protein levels.28,34

In interpreting our results, one should take account of some limitations including the limited sample size that can affect results, environmental factors, and various ethnic groups in southeast Iran. Another limitation of our analysis was that we only made our observations in the acute stage; thus, no longitudinal follow-up samples were available to assess their changes over time, leading to a cross-sectional analysis with only a limited robustness. We also assessed the diagnostic usefulness of renalase in an almost small sample. While it has been shown to be a probable biomarker, further studies with greater sample sizes are highly recommended if this hypothesis is to be clarified. Moreover, our results will be more valuable if we can test renalase activity in relation to renalase polymorphism. Since different ethnic groups exist in Iran, more research on all ethnic groups are advised to accept or deny the present findings of the study with larger sample sizes.

Conclusion

To summarize, higher circulating levels of renalase were associated with USAP+MetS. Moreover, the RNLS rs10887800 polymorphism was shown to be related to USAP+MetS. Higher risk for USAP+MetS was associated with the RNLS rs10887800 AG and GG genotypes. The present study suggests the need for further studies with larger sample sizes in order to investigate the probable early diagnostic value of renalase. It also supports its measurement in patients with USAP and MetS for a more specific risk assessment.